AFAP1, actin filament-associated protein 1; AML, acute myeloid leukemia; ARHGEF2, Rho/Rac guanine nucleotide exchange factor 2; BCAN, brevican; BDNF, brain-derived neurotrophic factor; BTBD1, BTB (POZ) domain containing 1; CDK-2, cyclin-dependent kinase 2; CR, complete response; CRC, colorectal cancer; CTCs, sequencing of circulating tumor cells; DFG, Asp-Phe-Gly; DOR, durable objective responses; ETV6, ETS translocation variant 6; EWG, electron-withdrawing group; FDA, U.S. Food and Drug Administration; FISH, fluorescence in situ hybridization; GBM, glioblastoma multiforme; HNSCC, head and neck squamous cell carcinoma; HTS, high-throughput screening; ICC, intrahepatic cholangiocarcinoma; IG-C2, Ig-like C2 type I; LMNA, lamin A/C; MASC, mammary analogue secretory carcinoma; MPRIP, myosin phosphatase Rho interacting protein; NACC2, NACC family member 2; NCCN, National Comprehensive Cancer Network; NFASC, neurofascin; NGF, nerve growth factor; NGS, next-generation sequencing of tumor tissue; NSCLC, non-small cell lung cancer; NT3, neurotrophin-3; NTRK fusion cancer; NTRK, neurotrophic receptor tyrosine kinase; Neurotrophic receptor tyrosine kinase fusions; OAK, osteoarthritis of the knee; ORR, overall response rate; PAN3, poly(A) nuclease 3; PPL, periplakin; PROTAC proteolysis targeting chimera, QKI; RABGTPase activating protein 1-like, RFWD2; RTK, receptor tyrosine kinase; SAR, structure­activity relationship; SBC, secretory breast carcinoma; SCYL3, SCY1 like pseudokinase 3; SQSTM1, sequestosome 1; Small-molecule inhibitor; TFG, TRK-fused gene; TP53, tumor protein P53; TPM3, tropomyosin 3; TPR, translocated promoter region; TRIM24, tripartite motif containing 24; TRK, tropomyosin receptor kinase; Tropomyosin receptor kinase; VCL, vinculin; VEGFR2, vascular endothelial growth factor receptor 2; quaking I protein, RABGAP1L; ring finger and WD repeat domain 2, E3 ubiquitin protein ligase